

Onderbouwend	Stof	Effect	Code
Lamba M. American Society for Clinical Pharmacology and Therapeutics. Annual meeting, Dallas TX, 2011. poster	tofacitinib + ciclosporine	↑ AUC tofacitinib 1.7x, ↓ C _{max} met 17% Regime: tofacitinib 10 mg op dag 6, ciclosporine 200 mg 2dd op dag 1 t/m 6; 10 vrijwilligers Auteurs: the results indicate that tofacitinib may need dose adjustment when administered together with cyclosporine	0A
SPC + EPAR Xeljanz	tofacitinib + ciclosporine	↑ AUC tofacitinib 1.7x (afgeleid uit fig. 1) Combinatie met ciclosporine vermijden zelfde getallen als Lamba 2011	1A?


Overig	Stof	Effect
SPC Xeljanz	tofacitinib + immunosuppress	gebruik dient te worden vermeden bij RA-patiënten in combinatie met krachtige immunosuppressiva zoals azathioprine, ciclosporine en tacrolimus, vanwege kans op verhoogde immunosuppressie en verhoogd risico op infectie.
Song GG. J Intern Med 2014; 29:656–63.	tofacitinib	A systematic review of randomized controlled trials (RCTs) that examined the efficacy and safety of tofacitinib in patients with active RA was performed. The safety outcomes did not differ between the tofacitinib 5- and 10-mg groups and placebo groups with the exception of infection in the tofacitinib 10-mg group (RR, 2.133; 95% CI, 1.268 to 3.590; p = 0.004). We did not directly compare the effects of tofacitinib at 5 and 10 mg twice per day. A dose-response relationship was not observed, and whether a dose of 10 mg twice daily is more effective than 5 mg is unclear.

Opmerkingen

Risicofactoren	
Mitigerende factoren	

	Interactie	Actie	Datum
Beslissing WFG	Ja	Ja	10 oktober 2017

Figuur 1. Invloed van andere geneesmiddelen op de farmacokinetiek van XELJANZ



Opmerking: De referentiegroep kreeg alleen XELJANZ toegediend
FK = farmacokinetiek, BI = betrouwbaarheidsinterval